IDEXX Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 6/6

IDEXX Laboratories ha aumentado sus beneficios a una tasa media anual de 15.5%, mientras que los beneficios de la industria de Medical Equipment han experimentado un descenso de 5.9% anual. Los ingresos han ido creciendo a una tasa media de 10.8% al año. La rentabilidad financiera de IDEXX Laboratories es de 56.9%, y sus márgenes netos son de 23.1%.

Información clave

14.9%

Tasa de crecimiento de los beneficios

15.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	-9.5%
Tasa de crecimiento de los ingresos	10.5%
Rentabilidad financiera	55.2%
Margen neto	23.3%
Próxima actualización de resultados	06 Aug 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero IDEXX Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:0J8P Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	3,725	867	925	199
31 Dec 23	3,661	845	902	191
30 Sep 23	3,588	823	888	183
30 Jun 23	3,514	791	877	183
31 Mar 23	3,431	699	858	259
31 Dec 22	3,367	679	851	255
30 Sep 22	3,340	670	848	257
30 Jun 22	3,309	664	840	249
31 Mar 22	3,274	735	821	164
31 Dec 21	3,215	745	796	161
30 Sep 21	3,135	757	770	154
30 Jun 21	3,047	728	777	152
31 Mar 21	2,858	674	739	146
31 Dec 20	2,707	582	735	141
30 Sep 20	2,591	497	717	138
30 Jun 20	2,475	460	674	134
31 Mar 20	2,457	437	681	135
31 Dec 19	2,407	428	669	133
30 Sep 19	2,351	423	657	128
30 Jun 19	2,291	407	642	123
31 Mar 19	2,252	390	638	120
31 Dec 18	2,213	377	632	118
30 Sep 18	2,170	330	621	117
30 Jun 18	2,117	307	610	115
31 Mar 18	2,045	284	596	112
31 Dec 17	1,969	263	575	109
30 Sep 17	1,906	277	561	106
30 Jun 17	1,862	263	547	104
31 Mar 17	1,820	245	534	102
31 Dec 16	1,775	222	522	101
30 Sep 16	1,732	214	516	101
30 Jun 16	1,690	202	502	100
31 Mar 16	1,637	192	493	99
31 Dec 15	1,602	192	482	100
30 Sep 15	1,554	174	475	99
30 Jun 15	1,531	182	467	99
31 Mar 15	1,508	182	457	100
31 Dec 14	1,486	182	448	98
30 Sep 14	1,488	199	435	96
30 Jun 14	1,443	193	422	93
31 Mar 14	1,405	190	409	89
31 Dec 13	1,377	188	401	88
30 Sep 13	1,343	188	381	87
30 Jun 13	1,320	185	370	85

Ingresos de calidad: 0J8P tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (23.1%) de 0J8P son superiores a los del año pasado (20.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 0J8P han crecido un 15.5% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 0J8P en el último año (24.4%) supera su media de 5 años (15.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 0J8P en el último año (24.4%) superó al de la industria Medical Equipment 17.9%.

IDEXX Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Recent updates

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold US$3.1m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$2.70 (vs US$1.57 in 2Q 2022)

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Independent Director recently sold US$950k worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

Full year 2022 earnings released: EPS: US$8.12 (vs US$8.74 in FY 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Investor sentiment improved over the past week

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Insufficient new directors

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$1.57 (vs US$2.37 in 2Q 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold US$127k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

Investor sentiment deteriorated over the past week

Executive VP & Chief Commercial Officer recently sold US$2.9m worth of stock

Third quarter 2021 earnings released: EPS US$2.06 (vs US$1.71 in 3Q 2020)

President recently sold US$4.1m worth of stock

Insider recently sold US$7.1m worth of stock

Second quarter 2021 earnings released: EPS US$2.37 (vs US$1.75 in 2Q 2020)

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

Chief Marketing Officer & Senior VP recently sold US$1.1m worth of stock

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Chief Marketing Officer & Senior VP recently sold US$1.6m worth of stock

Independent Director has left the company

Senior Advisor & Director recently sold US$276k worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold US$163k worth of stock

New 90-day high: US$545

New 90-day high: US$540

Dr. Rebecca M. Henderson Intends to Retire from the Board of Directors of IDEXX Laboratories, Inc

Independent Director recently sold US$5.8m worth of stock

Full year 2020 earnings released: EPS US$6.82 (vs US$4.97 in FY 2019)

Revenue beats expectations

­­IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative

IDEXX Laboratories, Inc. to Report Q4, 2020 Results on Feb 02, 2021

Idexx Laboratories, Inc. Elects Asha S. Collins as an Independent Class I Director

Senior Advisor & Director recently sold US$9.0m worth of stock

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

IDEXX Laboratories, Inc. to Report Q3, 2020 Results on Oct 29, 2020

First half earnings released

IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative

Desglose de ingresos y gastos
Beta